Efavirenz, lamivudine, and tenofovir and Lopinavir and ritonavir interaction

Efavirenz, lamivudine, and tenofovir and Lopinavir and ritonavir: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Lopinavir and ritonavir (Kaletra) label · effective 2026-07-23

Major

KALETRA once daily in combination with efavirenz or nevirapine is not recommended [see Dosage and Administration ( 2 )] .

Drug interactionsnames Efavirenz, lamivudine, and tenofovirView label on DailyMed
Moderate

Non-nucleoside Reverse Transcriptase Inhibitors: efavirenz*, nevirapine* ↓ lopinavir Increase the dose of KALETRA tablets to 500/125 mg when KALETRA tablet is co-administered with efavirenz or nevirapine.

Drug interactionsnames Efavirenz, lamivudine, and tenofovirView label on DailyMed
Moderate

Nucleoside Reverse Transcriptase Inhibitor: tenofovir disoproxil fumarate* ↑ tenofovir Patients receiving KALETRA and tenofovir should be monitored for adverse reactions associated with tenofovir.

Drug interactionsnames Efavirenz, lamivudine, and tenofovirView label on DailyMed
Moderate

Potential for KALETRA to Affect Other Drugs Lopinavir/ritonavir is an inhibitor of CYP3A and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.

Drug interactionsby drug classView label on DailyMed
Moderate

Although not observed in the KALETRA/ketoconazole drug interaction study, co-administration of KALETRA and other drugs that inhibit CYP3A may increase lopinavir plasma concentrations.

Drug interactionsby drug classView label on DailyMed

From the Efavirenz, lamivudine, and tenofovir (SYMFI) label · effective 2019-10-15

Major

Lactic Acidosis and Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs and other antiretrovirals.

Warnings and precautionsby drug classView label on DailyMed
Major

• SYMFI should not be administered with other antiretroviral medications for the treatment of HIV-1 infection.

Drug interactionsby drug classView label on DailyMed
Major

Not Recommended with Other Antiretroviral Medications SYMFI is a complete regimen for the treatment of HIV-1 infection; therefore, it should not be administered with other antiretroviral medications for treatment of HIV-1 infection.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.